Summary
This Form 8-K filing from Pfizer Inc. (PFE) dated June 14, 2007, clarifies previously announced findings from a retrospective analysis of a U.S. managed-care database concerning Lipitor. Initially, Pfizer reported significant additional cardiovascular risk reductions for Lipitor compared to simvastatin in both primary and secondary analyses. However, upon subsequent review, the company has revised these findings. The primary analysis, which adjusted for expected LDL cholesterol differences, now shows a 10% additional risk reduction for Lipitor, which is not statistically significant. The secondary analysis, examining risk reduction from day one of therapy, still shows a statistically significant 22% additional risk reduction for Lipitor.
Key Highlights
- 1Pfizer is clarifying previous announcements regarding a Lipitor cardiovascular risk reduction study.
- 2A retrospective analysis of a U.S. managed-care database compared Lipitor and simvastatin.
- 3The primary analysis, after adjusting for LDL cholesterol levels, showed a 10% additional cardiovascular risk reduction for Lipitor, which is not statistically significant.
- 4The secondary analysis, looking at risk reduction from day one of therapy, showed a statistically significant 22% additional cardiovascular risk reduction for Lipitor.
- 5The initial announcement had reported a 14% statistically significant reduction in the primary analysis and a 26% statistically significant reduction in the secondary analysis.
- 6This filing serves to correct and provide more precise data on the comparative effectiveness of Lipitor versus simvastatin in reducing cardiovascular events.
Frequently Asked Questions
The main purpose is to clarify and correct previously reported results from a retrospective analysis comparing the cardiovascular risk reduction of Lipitor versus simvastatin in a managed-care database.
Originally, Pfizer announced a significant 14% additional cardiovascular risk reduction for Lipitor in the primary analysis and a 26% significant reduction in the secondary analysis. The revised results indicate a non-statistically significant 10% reduction in the primary analysis and a statistically significant 22% reduction in the secondary analysis.
The company's subsequent review determined that the 10% additional risk reduction observed in the primary analysis, after adjustments for expected differences in LDL cholesterol lowering, did not meet the threshold for statistical significance.
The filing refines the understanding of Lipitor's comparative benefit. While the statistically significant benefit in the secondary analysis remains, the primary analysis result is no longer considered statistically significant, potentially influencing how the drug's incremental benefit is perceived, especially after accounting for cholesterol-lowering effects.